Effectiveness and safety of pidotimod in recurrent respiratory infections in children: a pilot study

Background: Recurrent respiratory infections (RRIs) are common in children especially in age 1 to 6 years. Pidotimod, an immunostimulant has been found to lower the recurrences of RRIs and improve the quality of life. The Objective of this study was to assess the efficacy and safety of pidotimod in children with recurrent respiratory infections (RRIs).Methods: In this single-centre, prospective, observational study, children aged 2 to 15 years diagnosed with RRIs were included. RRIs were defined as occurrence of 3 or more episodes of acute respiratory infections (ARIs) or more than 15 days of respiratory symptoms in the past 3 months. These children were treated with pidotimod in addition to standard care treatment. Treatment duration was two months and the follow-up continued for three months. Number of RRIs and severity of RRIs, antibiotic courses and rate of hospitalization before and after treatment were compared.Results: In total 25 children included in the study, mean age was 7.34'3.63 years. Among them, 68% were males. After treatment with pidotimod, there was significant reduction in mean number of ARI episodes (3.84'0.85 at baseline to 0.48'0.51 at follow-up, p<0.0001). Also, there was significant reduction in the duration of acute infectious episodes (p<0.0001), need of antibiotic courses (p<0.0001) and rates of hospitalization (p<0.0001). No safety concerns were identified and pidotimod was well tolerated.Conclusions: Addition of pidotimod to the standard treatment in children with RRIs significantly reduces the recurrence, duration of repeat infectious episodes, need of antibiotic treatments and future rates of hospitalizations. These findings support previous data.

Effect of pidotimod granules combined with Carboxymethyl starch sodium solution in recurrent respiratory tract infection and immune function / 中国生化药物杂志

Objective To investigate the effect of pidotimod granules and Carboxymethyl starch sodium solution in treating children with recurrent respiratory tract infection curative effect and effect on immune function of children.Methods 128 cases of children with recurrent respiratory tract infection in our hospital from June 2013 to June 2016 were selected and divided into treatment group and control group with 64 cases in each group. Children in the control group were treated with Carboxymethyl starch sodium solution, the treatment group was given pidotimod granules on the basis of the control group.Two groups of children were treated for 12 weeks.The therapeutic effects of the two groups were compared, the changes of immune function before and after treatment, cough, fever, lung rales disappear time, and the incidence of adverse reactions.Results The total effective rate of the treatment group (90.62%) was higher than the control group (75.00%), the difference was statistically significant (P<0.05), the levels of IgA, IgM and IgG increased after treatment in both groups, the levels of IgA, IgM and IgG in the treatment group were higher than those in the control group, the difference was statistically significant (P<0.05), the levels of CD3 +, CD4 +and CD4 +/CD8 +increased after treatment in both groups, and the levels of CD3 +, CD4 +and CD4 +/CD8 +in the treatment group were higher than those in the control group, the difference was statistically significant (P<0.05), the treatment group in children with cough, fever, pulmonary rales disappeared faster than the control group, the difference was statistically significant (P <0.05), two groups were no obvious adverse reactions.Conclusion Pidotimod granules combined with carboxymethyl starch sodium solution in treating children with recurrent respiratory tract infections is effective, and could significantly improve the immune function of children.

Effects of Pidomorph on serum immune cell level and T cell subsets in children with bronchial asthma / 中国生化药物杂志

Objective To evaluate the effects of Pidomorph on serum immune cell level and T cell subsets in children with bronchial asthma.Methods 140 pediatric patients with bronchial asthma from January 2014 to October 2016 in our hospital were randomly divided into experimental group and control group according to the order of admission,70 cases in each groups.The control group was treated with conventional glucocorticoid drugs,and the experimental group was treated with pidotimod.The total effective rate of clinical treatment,the rate of rapid breathing in the flow rate,forced expiratory peak value,forced breathing vital capacity were compared between two groups three weeks after treatment,and the serum levels of immune cells(IgA,IgG,IgM)and T cell subsets(CD3+,CD4+,CD8+)were compared before and after treatment.Results The total effective rate was 92.86％(65/70)in the experimental group and 72.86％(51/70)in the control group,the total effective rate in the experimental group was significantly higher than that in the control group(P<0.05); Forced breathing speed in the speed,forced expiratory peak value,forced breathing vital capacity in the experimental group were better than the control group(P<0.05); After treatment,the levels of serum immune cells(IgA,IgG,IgM)in the experimental group were significantly higher than those in the control group(P<0.05); After treatment,the levels of T cell subsets(CD3+,CD4+,CD8+)in the experimental group were significantly higher than those in the control group(P<0.05).Conclusion Pidotimod is effective and safe in the treatment of bronchial asthma in children,it can effectively regulate T cell subsets and improve the immune function of children with asthma.

Research on the impact of pidotimod combined with antiviral drugs on immunologic function and myocardial enzyme spectrum in children with infectious mononucleosis / 中国生化药物杂志

Objective To investigate the effect of pidotimod combined with antiviral drugs on immunologic function and myocardial enzyme spectrum in children with infectious mononucleosis.Methods 94 cases of children with infectious mononucleosis selected in Wenzhou Children's hospital were randomly divided into control group and research group,47 cases in each group.The control group were given conventional antiviral treatment; On this basis,the research group were given pidotimod,2 weeks for one period of treatment.Before and after treatment,immune function,cell factors and myocardial enzyme spectrum were tested,the clinical symptoms,signs,the curative effect and complications were observed and compared.Results Compared with before treatment,after treatment,serum CD4+,CD4+/CD8+ IgA and IgG increased,CD8+ decreased,TNF alpha,IL-6,AST,LDH,CK,CK-MB decreased(P<0.05).Compared with the control group,in the research group,CD4+,CD4+/CD8+,IgA and IgG content is higher,CD8+ content is lower,the TNF alpha,IL-6,AST,LDH,CK,CK-MB content is lower(P<0.05).The time of antipyretic,angina fade,narrow lymph nodes,liver and spleen shrinks and length of hospital stay in the research group were shorter than that in the control group(P<0.05).The effective rate was 74.47％in the control group,lower than 91.49％of research group(P<0.05).Conclusion The curative is exact that pidotimod combined with antiviral drugs on the treatment of infectious mononucleosis.It could improve immune function,reduce myocardial enzyme spectrum and inflammation.

Clinical efficacy and safety of ambrocol oral liquid combined with pidotimod oral liquid in allergic asthma in children with mite / 中国生化药物杂志

Objective To investigate the clinical curative effect and safety of ambrocol oral liquid combined with pidotimod oral liquid in the treatment of children with mite allergic asthma.Methods 54 cases of children with mite allergic asthma from December 2014 to December 2015 were selected and randomly divided into the control group and experimental group,27 cases in each group.On the basis of routine treatment,the control group was given pidotimod oral solution 10mL,once a day,oral; on the basis of the control group,the experimental group was treated with ambrocol oral solution 10mL,twice a day,oral.Interleukin-2(IL-2),interleukin-4(IL-4),immunoglobulin E(IgE)levels,the efficacy and safety of the two groups were measured before and after treatment.Results After treatment,compared with the control group,the serum levels of IL-2 were higher,and the levels of IL-4、IgE were lower in the experimental group,the difference was statistically significant(P<0.05),the treatment efficiency of the experimental group(92.59％)was significantly higher than that of the control group(81.48％),the difference was statistically significant(P<0.05).Conclusion The ambrocol oral liquid combined with pidotimod oral liquid can significantly improve the serum level of IL-2,and reduce the serum level of IL-4,IgE in children with mite allergic asthma,improve clinical efficacy.

Clinical Study on Pidotimod in the Treatment of Bronchial Asthma Complicated with Recurrent Respiratory Tract Infection in Children / 中国药房

OBJECTIVE:To investigate the clinical effects of pidotimod in the bronchial asthma complicated with recurrent re-spiratory tract infection,and its effects on immunoglobulin and related indexes. METHODS:A total of 120 bronchial asthma pa-tients with recurrent respiratory tract infection selected from our hospital during Mar. 2011-May 2013 were divided into trial group and control group according to random number table,with 60 cases in each group. Control group received routine corticosteroid therapy,and trial group was additionally given Pidotimod oral solution 0.4 g,po,bid,for 14 d,on the basis of control group. Clinical indexes(the times of respiratory infection,the duration of fever,cough,wheezing attack and antibiotics use),serum in-dexes [β-defensin-1(hBD-1),immunoglobulin A(IgA),IgG,IgM,UREA,ALT],the results of pharynx test before and after treatment,and the occurrence of ADR were observed in 2 groups. RESULTS:Before treatment,there was no statistical signifi-cance in clinical indexes,serum indexes,the results of pharynx test between 2 groups(P>0.05). After treatment,clinical indexes of trial group were significantly lower or shorter then before treatment or control group,while serum levels of hBD-1,IgA and IgG were significantly higher than before treatment or control group,with statistical significance(P0.05). The types and number of pathogenic bacteria of respiratory tract infection were decreased significantly in 2 groups,and the trial group was significantly less then the control group,with statistical significance(P<0.05). No obvious ADR was found in 2 groups. CONCLUSIONS:Pidotimod shows good clinical effects on bronchial asthma complicated with recurrent re-spiratory tract infection,can improve immunity and reduce the types and number of pathogenic bacteria with good safety.

Effect of Pidotimod Combined with Budesonide Aerosol Inhalation on the IL-4, IFN-γImmunoglobulin and T Cell Subsets of Children with Bronchial Asthma / 现代生物医学进展

Objective:To investigate the influence ofpidotimod combined with budesonide aerosol inhalation on the IL-4,IFN-γ,immunoglobulin and T cell subsets of children with bronchial asthma.Methods:92 cases of children with bronchial asthma in our hospi tal from June 2015 to June 2016 were selected as the research objects and randomly divided into the observation group and the control group.The control group was given budesonide suspension treatment,and the observation group was treated by pidotimod oral liquid on the base of the control group.The changes of serum IgA,IgG,IgM,CD3+,CD4+,CD8+ and CD4+CD8+ before and after treatment were de tected and compared between the two groups.Results:Before treatment,there was no significant difference in the serum IL-4,IFN-γ,IgA,IgG,IgM,CD3+,CD4+,CD8+ and CD4+/CD8+ between two groups (P＞0.05).Compared with those before treatment,the serum level of IL-4 was significantly decreased,in the observation group,while the IFN-γ,IgA,IgG,IgM,CD3+,CD4+,CD4+/CD8+ levels were significantly increased afrer treatment (P＜0.05).The IFN-γ,IgA,IgG,IgM,CD3+,CD4+,CD8+ and CD4+/CD8+ of control group showed no significant change before and after treatment (P＞0.05),only the serum IL-4 level was significantly decreased (P＜0.05).After treatment,the IL-4,IFN-γ,IgA,IgG,IgM,CD3+,CD4+,CD8+ and CD4+/CD8+ of observation group were better than those of the control group (P＜0.05).Conclusion:Compared with budesonide alone,pidotimod combined with budesonide could significantly regulate the immune function of children with bronchial asthma.

Effect of pidotimod combined with Yanhuning on children with refractory Mycoplasma pneumonia clinical symptoms and immune function / 中国生化药物杂志

Objective To investigate the the curative effect of pidotimod combined with Yanhuning for children with refractory mycoplasma pneumonia(RMPP).Methods90 patients with RMPP from January 2013 to January 2015in shengzhou maternal and child health care hospital were divided into 3 groups, including Yanhuning group(A group), azithromycin combined with Yanhuning group(B group)and pidotimod combined with Yanhuning group(C group).And the total effective rate, the clinical symptoms, immune function parameters were analyzed.ResultsThe regulation of immune function in C group was more significant than that in A group and B group, the prognosis was better, and the repeated times and continuous time were decreased (P<0.05).ConclusionPidotimod combined with Yanhuning treatment of RMPP can regulate the immune function of children, improve clinical symptoms, it is worthy of popularization.

Effect of pidotimod on immunologic functions and clinical curative efficacy for patients undergoing recurrent respiratory tract infections / 药物评价研究

Objective To evaluate the effect of pidotimod combined with antibacterials on the immunologic functions and clinical curative efficacy for patients undergoing recurrent respiratory tract infections.Methods Patients with recurrent respiratory tract infections (150 cases) were enrolled in Matemal and Child Health Hospital of Guangyuan from August 2013 to January 2016,which divided to two groups randomly,Group A (n =75) accepted traditional antibacterials treatment,and Group B (n =75) adopted pidotimod combined with antibacterials.The clinical symptom and immunologic functions of patients during treatment were tested,and the clinical curative efficacy of patients was evaluated in the follow-up period.Results After treatment,the disappear time of cough,fever,tonsil inflammation and pulmonary wheezing in treatment group was significantly shorter than that of control group (P ＜ 0.05).After treatment,the levels of serum immunoglobulin in two groups were higher than those before treatment (P ＜ 0.05),and the treatment group was significantly higher than control group (P ＜ 0.05).After treatment,the relative activities of CD3+,CD4+,CD8+,and NK cells in two groups increased significantly (P ＜ 0.05),the relative content of CD4+/CD8+ was also increased (P ＜0.05),and the improvement of above indexes in the treatment group was more obvious than those in control group (P ＜ 0.05).After treatment,total effective rate of treatment group was significantly higher than that of control group (P ＜ 0.05),the recurrence of infection in the treatment group is significantly lower than that in the control group (P ＜ 0.05),and the recurrence duration was significantly shorter than control group (P ＜ 0.05).Conclusion The clinical curative of pidotimod combined with antibacterials was remarkable for patients of recurrent respiratory tract infections,which deserved popularization not only improving the immunologic functions,but also decreasing the times of recurrence.

Clinical Observation of Pidotimod Combined with Ceftriaxone Sodium in the Treatment for Elderly Bronchopneumonia / 中国药房

OBJECTIVE:To observe therapeutic efficacy and safety of pidotimod combined with ceftriaxone sodium in the treatment of elderly bronchopneumonia.METHODS:A total of 164 elderly patients with bronchopneumonia were randomly divided into observation group (82 cases) and control group (82 cases).Based on routine treatment,control group was given Ceftriaxone sodium for injection 2 g added into 0.9％ Sodium chloride solution 100 mL intravenously,once a day.Observation group was additionally given Pidotimod oral solution 7 mL,twice a day,on the basis of control group.Both group were treated for 2 weeks.Clinical efficacy,defervescence time,cough and wheezing disappearance time,chest radiograph improvement time and average hospitalization time were observed in 2 groups.The serum levels of TNF-αt,IL-6,hs-CRP,IgG,IgA and IgM before and after treatment,the occurrence of ADR were observed.RESULTS:Total response rate of observation group (95.12％) was significantly higher than that of control group (81.71％);and defervescence time,cough and wheezing disappearance time,chest radiograph improvement time and average hospitalization time were significantly shorter than control group,with statistical significance (P＜0.05).After treatment,serum levels of TNF-α,IL-6,hs-CRP and IgM in 2 groups were significantly lower than before treatment,and the observation group was significantly lower than the control group;the levels of IgG and IgA in 2 groups were significantly higher than before treatment,and the observation group was significantly higher than the control group,with statistical significance(P＜0.05).There was no statistical significance in the incidence of ADR between 2 groups (P＞0.05).CONCLUSIONS:Pidotimod combined with ceftriaxone shows significant therapeutic efficacy for elderly bronchopneumonia and improve clinical symptoms without increasing the occurrence of ADR.

Improvements of immune function and clinical symptoms of pidotimod combined with Yanhuning for children with refractory mycoplasma pneumoniae pneumonia / 中国基层医药

Objective To investigate the curative effect of pidotimod combined with Yanhuning for children with refractory mycoplasma pneumoniae pneumonia(RMPP).Methods 150 patients with RMPP in our hospital were divided into 3 groups,including Yanhuning group(A group),azithromycin combined with Yanhuning group(B group) and pidotimod combined with Yanhuning group(C group).And the total effective rate,the clinical symptoms,immune function parameters were analyzed.Results Compared to A group,the effective rate of B group and C group were sig-nificantly higher(all P <0.05),but there was no statistically significant difference between B group and C group. Compared to A group,the defervescence time,cough disappeared time and rales disappeared time were significantly shorter(all P <0.05),and the effect in C group was better than that in B group (all P <0.05).Compared to normal control group,CD +3 ,CD +4 ,CD +4 /CD +8 and CD +16 CD +56 in A group,B group and C group before the treatment were sig-nificantly lower(P <0.05),but IgG,IgM,CD +8 and CD +19 were significantly higher(all P <0.05).And CD +3 ,CD +4 , CD +4 /CD +8 and CD +16C D +56 in C group were significantly higher(all P <0.05)after the treatment.During follow -up, compared to A group,the recurrence rate and time in B group and C group were significant reduction(all P <0.05), and the recurrence rate and time in C group were less than that in B group (all P <0.05).So the regulation of immune function in C group was more significant than that in A group and B group,the prognosis was better,and the repeated times and continuous time were decreased.Conclusion Pidotimod combined with Yanhuning treatment of RMPP can regulate the immune function of children,improve clinical symptoms,which should be promoted.

Clinical Observation of Pidotimod Combined with Montelukast Sodium in the Treatment of Children with Bronchial Asthma / 中国药房

OBJECTIVE:To observe clinical efficacy and safety of pidotimod combined with montelukast sodium in the treat-ment of children with bronchial asthma. METHODS:120 children with bronchial asthma were randomly divided into control group and observation group,with 60 cases in each group. Both group were given routine treatment as aerosol inhalation of glucocorticoid and anti-infective treatment. Control group was additionally given Montelukast sodium chewable tablet 5 mg orally,qd,at bed-time;observation group was additionally given Pidotimod capsule 0.4 g,qd,on the basis of control group. Both group received treatment for consecutive 3 months. Clinical efficacies of 2 groups were observed as well as IL-4,IFN-γ,IgE,T lymphocyte sub-set and lung function indexes of 2 groups before and after treatment. The occurrence of ADR were compared between 2 groups. RE-SULTS:The effective rate of observation group was 88.3%,which was significantly higher than that of control group (61.7%). There was no statistical significance in IL-4,IFN-γ,IgE,T lymphocyte subset and lung function indexes between 2 groups before treatment(P>0.05). After treatment,IL-4,IFN-γ,IgE,CD4+,CD4+/CD8+ and lung function of 2 groups were improved signifi-cantly,and the observation group was significantly better than the control group,with statistical significance(P0.05). CONCLUSIONS:Pidotimod combined with monte-lukast sodium is effective for children with bronchial asthma,and can significantly relieve airway inflammation,enhance immunity and improve lung function with good safety.

The effect of pidotimod oral liquid in treatment of bronchial asthma in children and its influence on the immune function / 中国基层医药

Objective To explore the clinical efficacy of pidotimod oral liquid in the treatment of children with bronchial asthma,and its effect on immune function.Methods 260 children of bronchial asthma were selected, and they were divided into two groups by random number table method.The control group was given routine treatment, while the observation group was given pidotimod oral liquid on the basis of conventional treatment.The clinical efficacy and immune function index were compared between the two groups.Results The effective rate of the observation group was 93.85%,which was higher than 76.92% of the control group,the difference was statistically significant (χ2 =7.86,P 0.05).After treatment in the observation group,the FVC was (398 ±0.66)L,FEV1 was (307 ± 0.29)L,PEF was (3.58 ±0.42)L/min,and those were increased significantly compared with before treatment and the control group,the differences were statistically significant (t =7.99,853,8.27,6.88,7.12,6.73,all P 0.05).After treatment,CD +3 was (6.974 ±3.21 )%,CD +4 was (42.95 ±4.76 )%,the ratio of CD +4 /CD +8 was (1.38 ±0.44)% of the observation group,which were significantly increased compared with pre -treatment and the control group,the CD +8 of the observation group was (24.10 ±2.96),and it was obviously lower than pre -treatment and the control group,the differences were statistically significant (t =8.43,7.55,7.54,7.51,6.74,6.55,all P <0.05).Conclusion Pidotimod oral liquid in treatment of bronchial asthma in children can significantly improve the pulmonary function and immune function of the children,the curative effect is remarkable,and the application value is high,which can carry on clinical promotion.

The effect of pidotimod granules combined with Yupingfeng granules in the treatment of children with recur-rent respiratory infection / 中国基层医药

Objective To investigate the effect of pidotimod granules combined with Yupingfeng granules in the treatment of children with recurrent respiratory infection.Methods A total of 124 patients in the treatment of children′s immunologic function with recurrent respiratory infection were taken into this research.124 patients were divided into OBG(63 patients)group and COG(61 patients)group according to random number table and treated with pidotimod granules and Yupingfeng granules.Statistics of children′s treatment in the two groups were collected and analyzed after research.Results In OBG group,there were 33 excellent cases,28 effective cases,2 void cases,and the treatment efficiency was 96.83%,which were better than those in COG group(χ2 =8.796,9.054,8.931,9.135, all P <0.05).In OBG group,the extinction time of fever,moist rale,expectoration and chest pain were significantly shorter than those in COG group(t =8.562,9.025,8.747,8.637,all P <0.05).The differences between the two groups after treatment in IMF were statistically significant (all P <0.05 ).Conclusion Pidotimod granules and Yupingfeng granules has perfect effect in the treatment of children′s immunologic function with recurrent respiratory infection,which is worthy of promotion.

Clinical Efficacy of Loratadine Combined with Pidotimod in the Treatment of Children with Recurrent Re-spiratory Tract Infection and Effect on Immune Function / 中国药师

Objective:To study the clinical efficacy of loratadine combined with pidotimod in the treatment of children with repeat-ed respiratory tract infection and the effect of the combination on immune function. Methods:Totally 78 cases of patients with repeated respiratory tract infection were randomly divided into the observation group ( n=39 ) and the control group ( n =39 ) . Both of the groups were treated with the routine correct treatment, and the control group was treated with pidotimod and the observation group was treated with loratadine combined with pidotimod with the treatment course of 8 weeks. The clinical efficacy, clinical symptoms, signs improvements, changes of immune function markers level and incidence of adverse drug reactions between the two groups were observed and compared. Results:The total effective rate of the observation group was significantly higher than that of the control group ( P0. 05). Conclusion:The clinical efficacy of loratadine com-bined with pidotimod in the treatment of children with repeated respiratory tract infection is effective, which can improve the clinical symptom and signs and enhance the immune function of children significantly.

Clinical Observation of Pidotimod Combined with Triamcinolone Acetonide in the Treatment of Oral Lichen Planus / 中国药房

OBJECTIVE:To observe the efficacy and safety of pidotimod combined with triamcinolone acetonide in the treat-ment of oral lichen planus(OLP). METHODS:Data of 60 patients with OLP were retrospectively analyzed and divided into obser-vation group(35 cases)and control group(25 cases)by different medication. Control group was treated with triamcinolone aceton-ide 1 ml+2% Lidocaine injection 1 ml,embrocated in the local lesion area according to lesion size,3 times a day;observatioh group was additionally treated with Pidotimod dispersible tablets 800 mg between meals based on the treatment of control group, twice a day,and then changed to 800 mg,orally,once a day after 2 weeks. The treatment course was 4 weeks. The clinical effica-cy and incidence of adverse reactions in 2 groups were observed. RESULTS:After 1 and 3 month(s),the total effective rates in ob-servation group were significantly higher than control group,the difference was statistically significant(P0.05). CONCLUSIONS:Pidotimod combined with triamcinolone acetonide has significant efficacy in the treatment of OLP,with good safety.

Enhancement of epitope vaccines from W2b2a of Toxoplasma gondii potency using two kinds of immunomodulating agents in mice / 中国免疫学杂志

Objective:To observe the effect of Pidotimod and Thalidomid to enhance the immune response and protective immunity induced by the epitope Vaccines From W2b2a of Toxoplasma gondii in mice.Methods:Mice were immunized intramuscularly with Pidotimod and pcDNA3-W2b2a,thalidomide and pcDNA3-W2b2a,respectively,then the immune response and the survival time of mouse attacked by Toxoplasma gondii were observed.Results:After the immunization,the level of IFN-γin sera of mice inculated with pcDNA3-W2b2a and Pidotimod,pcDNA3-W2b2a and Freund adjuvant,pcDNA3-W2b2a and Thalidomid were significantly higher than pcDNA3-W2b2a (all P<0.05).After the immunization,IgG,CD4+/CD8+T cell ratio ,proliferation of T cell induced by pcDNA3-W2b2a and Pidotimod,pcDNA3-W2b2a and Freund adjuvant were higher than pcDNA3-W2b2a,pcDNA3-W2b2a and thalidomid ( all P<0.05).After challenged with highly virulent tachyzoites,the mean survival time in immunized groups were significantly longer than control group (all P<0.05).Conclusion:Pidotimod ,Thalidomid adjuvant can increase protective immunity of epitope Vaccines From W2b2a of Toxoplasma gondii in mice.

Application of pidotimod oral solution in children with recurrent respiratory tract infections / 中国医师进修杂志

Objective To study the application value of pidotimod oral solution in children with recurrent respiratory tract infections (RRTIs).Methods Ninety-two children with RRTIs were divided into observation group and control group by random digits table method with 46 cases each.The children in control group were given conventional treatment.The children in observation group were added pidotimod oral solution on the basis of conventional treatment.The serum immunoglobulin (lg) G,IgM,IgA,and peripheral blood T lymphocyte subgroup (CD3+,CD4+,CD8+) before and after treatment,improvement of clinical symptoms and signs,the recurrence time of respiratory tract infections during 1 year after treatment,and untoward reaction were compared between 2 groups.Results The IgG,IgM and IgA levels after treatment in observation group were significantly higher than those in control group:(9.98 ± 2.26) g/L vs.(8.49 ± 2.23) g/L,(1.27 ± 0.28) g/L vs.(1.10 ± 0.21) g/L,(0.95 ± 0.27) g/L vs.(0.72 ± 0.23) g/L,and there were statistical differences (P ＜ 0.05).The CD3+ and CD4+ levels after treatment in observation group were significantly higher than those in control group:0.706 ± 0.087 vs.0.630 ± 0.069,0.456 ± 0.047 vs.0.348 ± 0.034,and CD8+ level was significantly lower than that in control group:0.177 ± 0.046 vs.0.212 ± 0.041,and there were statistical differences (P ＜ 0.05).The time to defervesce,disappearing time of coughing,disappearing time of tonsil swelling and disappearing time of lung rale in observation group were significantly shorter than those in controlgroup:(2.82±0.71)d vs.(3.86± 1.11) d,(4.26± 1.54)d vs.(5.69± 1.82) d,(3.12± 1.02) d vs.(4.67 ± 1.40) d,(3.35 ± 1.58) d vs.(4.75 ± 1.58) d,and there were statistical differences (P ＜ 0.05).The recurrence time of respiratory tract infections during 1 year after treatment in observation group was significantly lower than that in control group:(5.08 ± 1.61) times vs.(7.25 ± 1.68) times,and there was statistical difference (P＜ 0.05).The untoward reaction was not found in the 2 groups.Conclusion Pidotimod oral solution has the prevention and treatment effect in children with RRTIs.

Effect of pidotimod,zinc gluconate,bifico on immune function in the treatment of infants with persistent / 中国基层医药

Objective To observe the effect of pidotimod,zinc gluconate,bifico on immune function in the treatment of infants with persistent chronic diarrhea,and to provide new options for clinical treatment.Methods The infants with persistent chronic diarrhea were selected as study objects,all patients were randomly divided into 40 patients of the observation group and 40 patients of control group,both group were given conventional treatment, which including ORS oral rehydration,vitamin supplements,electrolytes,correct acid -base balance,smecta.The con-trol group were given zinc gluconate and bifico(Bifico 20mg/kg,tid;oral zinc gluconate,10 -20mg/d (zinc compu-ting),tid),the observation group were given pidotimod(400mg/times,qd)on the basis of the control group.Both group had been treated for three weeks and been followed for 12month.The symptoms improvement was observed be-fore and after treatment,the time of stool frequency normalization and stool Characters normalization were recorded,the blood were extracted for detecting immunoglobulin (IgA,IgG)and T lymphocyte subsets (CD +3 ,CD +4 ,CD +8 ),the effect and Diarrhea relapses of follow -up of 6 months were evaluated.Results The time of stool frequency normali-zation and stool characters normalization in the observation group and the control group were (4.5 ±1.5 )d and (7.8 ±2.2)d,(4.3 ±1.6)d and(7.5 ±2.0)d,the observation group were significantly shorter than the control group,t =7.146,8.108,all P <0.01.The number of diarrhea relapses of follow -up of 6 months in observation group and the control group were (2.05 ±1.62)times and (3.73 ±1.65 )times,(3.38 ±2.12)times and (5.15 ± 2.32)times,the observaiton group were significantly less than the control group,t =3.845,3.636,all P <0.05.The IgA,IgG,CD +3 ,CD +4 ,of observation group and control group after treatment were (1.75 ±0.10)g/L vs.(1.50 ± 0.11)g/L,(8.95 ±1.42)g/L vs.(8.02 ±1.25)g/L,(57.5 ±6.6)% vs.(50.5 ±6.0)%,(39.5 ±3.5)% vs. (35.6 ±3.6)%,the observation group were significantly higher than before treatment (t =3.633,5.835,9.534, 6.427 and 3.274,3.643,4.732,3.658,all P <0.05).The IgA,IgG,CD +3 ,CD +4 of observation group after treatment was significantly higher than the control group (t =3.553,3.434,3.568,3.336,all P <0.05).The total effective rate of observation group was 90.0%,the control group was 72.5%,the difference was statistically significant(χ2 =6.664,P <0.05).Conclusion The method containing pidotimod,zinc gluconate and bifico can adjust the immune dysfunction,improve immune and humoral immunity,prevent secondary infection,improve nutrition,promote mucosal tissue repair,improve treatment efficacy and reduce the long -term recurrence,worthy of clinical use in the treatment of infants with persistent chronic diarrhea.

Study on effect of pidotimod on TH1/TH2 balance and immune factor in patients with severe trauma / 中国生化药物杂志

Objective To investigate effect of pidotimod on TH1/TH2 balance and immune factor in patients with severe trauma.Methods 90 cases with severe chest trauma patients were randomly divided into two groups.45 cases in control group were treated by conventional anti-inflammatory treatment, 45 cases in experimental group on base of control group with pidotimod 800mg /times, 1 times daily.After treatment, the serum levels of IL-4, IFN-γ, IL-2, IL-10, IL-17,IgM, IgA and IgG were compared.Results Compared with before treatment, indexes were improved(P<0.05). Compared with the control group, IL-4 level was lower, IFN-γlevel was higher, IFN-γ/IL-4 was higher(P<0.05).IL-2, IL-10, IL-17 level was higher(P<0.05).IgA, IgM, IgG level was higher(P<0.05).Conclusion Pidotimod can balance the TH1/TH2 in the patients with severe trauma, and adjust the serum levels of IgM, IgA and IgG,can be used in clinical application.